Navigation Links
Sagent Pharmaceuticals Announces Extension of Series A Financing
Date:5/20/2009

SCHAUMBURG, Ill., May 20 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has raised $30 million in a second Series A financing extension with pre-existing and new strategic investors. The round was again led by Vivo Ventures. This capital will be used to support upcoming product launches, development activities and strategic business objectives.

"Sagent's business model unites extensive pharmaceutical development, regulatory and manufacturing capabilities with the unique strength of our U.S. focused sales and marketing team to provide our hospital and clinical customers with a broad range of the highest quality injectable products," said Jeffrey M. Yordon, chief executive officer, founder and chairman of the board of Sagent Pharmaceuticals. "Since our inception in 2006, Sagent has successfully executed its strategy by filing more than 70 aNDAs to date, with more than 20 products expected in the market by year end. We appreciate our investors' continued confidence and commitment to Sagent."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
3. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
4. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
5. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
Breaking Medicine Technology: